ABBVIE INC
ABBVNYSETrading Snapshot
- Day Range
- $247.82 – $253.74
- 52-Week Range
- $190.75 – $267.47
- Volume
- $12.96B
- Avg Volume
- $11.71B
- Shares Outstanding
- 1.77B
- Next Earnings
- Sep 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $61.16B
- Last Q Revenue
- $16.99B
- P/E Ratio
- 68.9
- P/S Ratio
- 6.8x
- EPS (TTM)
- $3.56
- Dividend Yield
- 2.75%
Why Investors Own ABBV
- ✓High-growth profile — revenue up +21.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 28% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ABBVIE INC
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247
BNP Paribas analyst Navann Ty maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $218 to $247.
What Analysts Really Pressed LLY On This Quarter
Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.
AbbVie’s (ABBV) Botox Just Got A Step Closer To A Fifth Use
AbbVie (NYSE:ABBV) just moved a step closer to expanding one of its most recognizable brands. On August 4, the FDA accepted for review a supplemental Biologics License Application for Botox Cosmetic to treat masseter muscle prominence, the jaw-muscle bulge that can give a face a wider, squarer look. If cleared, Botox Cosmetic would become the […]
Eli Lilly Stock's Next Climb Runs Through A Pill, Not Just An Injection
The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.
Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?
The stock is up just 8% this year and could prove to be an undervalued buy.
We Said These 4 Dividend Aristocrats Could Soar. Here’s How They Did, Plus 3 New Picks.
Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where the dividend coverage story is quietly getting stronger.